Meeting
2014 ASCO Quality Care Symposium
Comparative effectiveness of antiangiogenesis inhibitors for second-line therapy of metastatic colorectal cancer.
Authors
Christina Xiaoyue Chen
Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA
Christina Xiaoyue Chen, Sarmad Sadeghi, Heinz-Josef Lenz, Afsaneh Barzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Science of Quality and Cost, Value, and Policy in Quality
Track
Science of Quality,Cost, Value, and Policy in Quality
Sub Track
Measuring Value and Costs
Citation
J Clin Oncol 32, 2014 (suppl 30; abstr 9)
DOI
10.1200/jco.2014.32.30_suppl.9
Abstract #
9
Poster Bd #
A8
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
A cost-effectiveness analysis of bevacizumab (BV) plus chemotherapy (CT) versus aflibercept (AFLI) plus CT in patients with metastatic colorectal cancer (mCRC) previously treated with BV.
First Author: Robert Morlock
Poster
2023 ASCO Annual Meeting
Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.
First Author: Mavis Obeng-Kusi
Poster
2017 Gastrointestinal Cancers Symposium
Cost effectiveness of maintenance bevacizumab in patients with metastatic colorectal cancer.
First Author: Joel Lange
Poster
2016 ASCO Annual Meeting
Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis.
First Author: Daniel A. Goldstein